Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE ...

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...

Data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at ...

"2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in ...

“2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

89Bio Inc ( (ETNB)) has released its Q4 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors. See what stocks are receiving Strong Buy ratings from top-rated analysts.

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...

Explore 89bio stock price, quotes ... Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.